ES2136247T3 - Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso. - Google Patents

Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso.

Info

Publication number
ES2136247T3
ES2136247T3 ES95302628T ES95302628T ES2136247T3 ES 2136247 T3 ES2136247 T3 ES 2136247T3 ES 95302628 T ES95302628 T ES 95302628T ES 95302628 T ES95302628 T ES 95302628T ES 2136247 T3 ES2136247 T3 ES 2136247T3
Authority
ES
Spain
Prior art keywords
azythromycin
show
dosage forms
oral dosage
food effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95302628T
Other languages
English (en)
Inventor
William J Curatolo
George H Foulds
Hylar L Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2136247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2136247T3 publication Critical patent/ES2136247T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA INVENCION PROPORCIONA EL USO DE AZITROMICINA EN LA FABRICACION DE UNA ADMINISTRACION ORAL QUE SE DESINTEGRE RAPIDAMENTE CON UNA ALTA BIOUTILIDAD PARA EL TRATAMIENTO DE UNA INFECCION MICROBIANA EN UN MAMIFERO QUE HA COMIDO O COMERA EN EL PERIODO QUE COMIENZA 1 HORA ANTES DE LA ADMINISTRACION Y TERMINA 2 HORAS DESPUES DE LA ADMINISTRACION.
ES95302628T 1994-04-29 1995-04-20 Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso. Expired - Lifetime ES2136247T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
ES2136247T3 true ES2136247T3 (es) 1999-11-16

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95302628T Expired - Lifetime ES2136247T3 (es) 1994-04-29 1995-04-20 Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso.

Country Status (31)

Country Link
US (2) US5605889A (es)
EP (1) EP0679400B1 (es)
JP (3) JPH07300420A (es)
KR (1) KR100354310B1 (es)
CN (1) CN1088362C (es)
AP (1) AP566A (es)
AT (1) ATE183395T1 (es)
AU (1) AU709328B2 (es)
CA (1) CA2148071C (es)
CO (1) CO4560547A1 (es)
DE (1) DE69511451T2 (es)
DK (1) DK0679400T3 (es)
DZ (1) DZ1877A1 (es)
ES (1) ES2136247T3 (es)
FI (1) FI952060A7 (es)
GR (1) GR3031290T3 (es)
HU (1) HUT75244A (es)
IL (1) IL113437A (es)
LV (1) LV10918B (es)
MA (1) MA23533A1 (es)
NO (1) NO314386B1 (es)
NZ (1) NZ548384A (es)
OA (1) OA10151A (es)
RU (1) RU2128998C1 (es)
SI (1) SI0679400T1 (es)
TN (1) TNSN95046A1 (es)
TW (1) TW499311B (es)
UA (1) UA34464C2 (es)
UY (1) UY23935A1 (es)
YU (1) YU49483B (es)
ZA (1) ZA953439B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ283160A (en) * 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
DK0801559T3 (da) * 1995-02-08 2002-06-17 Yamanouchi Europ Bv Fremgangsmåde til fremstilling af orale doseringsformer indeholdende et beta-lactam antibiotikum
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
DK0991415T3 (da) * 1997-12-22 2003-06-16 Schering Corp Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
HRP20010700B1 (hr) * 1999-03-31 2011-01-31 Janssen Pharmaceutica N.V. Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
ES2260047T3 (es) * 2000-07-25 2006-11-01 Laboratorio Silanes, S.A. De C.V. Proceso de etapa unica para la preparacion de 7,16-deoxi-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihidroxi-6-etil-3,5,9,11,13,15-hexametilbiciclo(11.2.1)hexadeca-1(2)-en-ona y obtencion de una forma nueva de 9-deoxo-9a-metil-9a-homoeritromicina a.
ATE306491T1 (de) 2000-08-23 2005-10-15 Wockhardt Ltd Verfahren zur herstellung von wasserfreiem azithromycin
CA2427596A1 (en) * 2000-11-06 2002-05-10 Life Technologies Corporation Dry powder cells and cell culture reagents and methods of production thereof
AU2002214290A1 (en) * 2000-11-15 2002-05-27 Masao Sugamata Preventives or remedies for endometriosis or uterine myoma
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
ES2310886T3 (es) * 2001-05-22 2009-01-16 Pfizer Products Inc. Nueva forma cristalina de azitromicina.
OA12845A (en) * 2001-08-21 2006-09-15 Pfizer Prod Inc Single dose azithromycin for treating respiratory infections.
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
US20040226852A1 (en) * 2003-02-19 2004-11-18 Michael Pesachovich Method of stabilizing azithromycin
EP1446010B1 (en) * 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
JP2005513099A (ja) * 2001-12-21 2005-05-12 ファイザー・プロダクツ・インク アジスロマイシンの直接的に圧縮可能な配合品
KR100669279B1 (ko) * 2001-12-21 2007-01-16 화이자 프로덕츠 인크. 아지트로마이신의 습식 제립 방법
WO2003061728A2 (en) * 2002-01-16 2003-07-31 Pepgen Corporation Oral administration of interferon-tau
JP2005526020A (ja) * 2002-02-01 2005-09-02 ファイザー・プロダクツ・インク アジスロマイシンの乾式造粒配合物
RU2203670C1 (ru) * 2002-02-19 2003-05-10 Акционерное Курганское общество медицинских препаратов и изделий "Синтез" Лекарственный препарат антибактериального действия и способ его получения
JP2005527508A (ja) * 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド 経口デリバリー用急速溶融多粒子製剤
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
AU2004238253B2 (en) * 2003-05-06 2011-01-27 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
EP1648473B1 (en) * 2003-07-24 2009-01-28 PLIVA HRVATSKA d.o.o. Single dose fast dissolving azithromycin
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
EP1694304A2 (en) * 2003-12-04 2006-08-30 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
CN1889931A (zh) * 2003-12-04 2007-01-03 辉瑞产品公司 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾－冻凝方法
AP2218A (en) * 2003-12-04 2011-04-20 Pfizer Prod Inc Azithromycin dosage forms with reduced side effects
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
EP1855693B1 (en) * 2005-03-07 2009-07-29 Teva Pharmaceutical Industries Ltd. Azithromycin powder for oral suspension compositions
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
JP4733120B2 (ja) 2005-05-26 2011-07-27 大日本住友製薬株式会社 医薬品組成物
KR20130016386A (ko) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
GB0618966D0 (en) * 2006-09-26 2006-11-08 Iti Scotland Ltd Cartridge system
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
HUE043949T2 (hu) 2012-02-06 2019-09-30 Boehringer Ingelheim Animal Health Usa Inc Szisztémásan ható hatóanyagokat tartalmazó, parazitaellenes, szájon át adagolt állatgyógyászati készítmények, eljárások és alkalmazásuk
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
CA2939604A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
EP0721324A1 (en) 1993-10-01 1996-07-17 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
NZ283160A (en) 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections

Also Published As

Publication number Publication date
DE69511451D1 (de) 1999-09-23
ATE183395T1 (de) 1999-09-15
HU9501206D0 (en) 1995-06-28
YU49483B (sh) 2006-08-17
JP2005015466A (ja) 2005-01-20
FI952060L (fi) 1995-10-30
SI0679400T1 (en) 1999-10-31
CN1088362C (zh) 2002-07-31
ZA953439B (en) 1996-10-28
FI952060A0 (fi) 1995-04-28
AP566A (en) 1996-11-22
DZ1877A1 (fr) 2002-02-17
KR100354310B1 (ko) 2002-12-26
NO951630D0 (no) 1995-04-28
NZ548384A (en) 2008-04-30
TNSN95046A1 (fr) 1996-02-06
RU2128998C1 (ru) 1999-04-20
OA10151A (en) 1996-12-18
MA23533A1 (fr) 1995-12-31
CA2148071A1 (en) 1995-10-30
TW499311B (en) 2002-08-21
EP0679400B1 (en) 1999-08-18
CO4560547A1 (es) 1998-02-10
UY23935A1 (es) 1995-09-12
HUT75244A (en) 1997-05-28
NO951630L (no) 1995-10-30
LV10918B (en) 1996-06-20
JPH07300420A (ja) 1995-11-14
GR3031290T3 (en) 1999-12-31
IL113437A0 (en) 1995-07-31
DE69511451T2 (de) 1999-12-09
AU709328B2 (en) 1999-08-26
CA2148071C (en) 2000-10-17
CN1114879A (zh) 1996-01-17
IL113437A (en) 2001-04-30
DK0679400T3 (da) 1999-12-06
USRE39149E1 (en) 2006-06-27
FI952060A7 (fi) 1995-10-30
LV10918A (lv) 1995-12-20
AU1771195A (en) 1995-11-09
US5605889A (en) 1997-02-25
JP2008231120A (ja) 2008-10-02
RU95106639A (ru) 1997-01-20
NO314386B1 (no) 2003-03-17
AP9500728A0 (en) 1995-04-30
KR950028764A (ko) 1995-11-22
YU27195A (sh) 1999-03-04
EP0679400A1 (en) 1995-11-02
UA34464C2 (uk) 2001-03-15

Similar Documents

Publication Publication Date Title
ES2136247T3 (es) Formas de dosificacion oral de azitromicina que no muestran un efecto alimento adverso.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
ES2080307T3 (es) Composiciones farmaceuticas.
ES2181873T3 (es) Fracciones de polifenoles del te, uso de las mismas y formulaciones que las contienen.
ES2156840T1 (es) Medicamento que contiene polisulfato de pentosano e implante para tratar la fibrosis.
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
Unny et al. A review on potentiality of medicinal plants as the source of new contraceptive principles
DE59509848D1 (de) Kombinationspräparat zur anwendung bei immunologischen erkrankungen
TR199801511T2 (xx) Farmas�tik bile�im.
ITRM920900A0 (it) Formulazione proteica coadiuvante nella prevenzione e cura delle parodontiti e di altre patologie batteriche del cavo orale.
PT1001775E (pt) Medicamento contendo ioimbina e arginina para tratamento de disfuncao erectil
ES2164753T3 (es) Tabletas organolepticamente estables para la limpieza de dentaduras.
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
AR028502A1 (es) Tratamiento de condiciones inflamatorias alérgicas
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
MX9405371A (es) Derivado de naftilo.
ES2099226T3 (es) Composiciones farmaceuticas de liberacion programada.
ES2062529T3 (es) Uso de alcoholes alifaticos, de c-20 a c-26, para la realizacion de un medicamento destinado al tratamiento de infecciones virales.
BR0308795A (pt) Amidas do ácido sulfamico
YU39396A (sh) Upotreba izolovanog prirodnog proteina gojaznosti za pripremu leka i njegova farmaceutska formulacija
IT8820880A0 (it) Composizioni erbicide a base di clomazone e metodi di impiego implicanti una maggiore tolleranza nel caso di colture di mais ed altre colture.
DE3872881D1 (de) Arzneimittelzusammensetzung zur vorbeugung und behandlung bakterieller und viraler krankheiten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 679400

Country of ref document: ES